Research programme: type IIb sodium-phosphate co-transporter inhibitors - SanofiAlternative Names: NaP2 inhibitors; NaPi2b inhibitors; Npt2b inhibitors; RDX 002; SLC34A2 inhibitors
Latest Information Update: 16 Jul 2016
At a glance
- Originator Ardelyx
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Type IIb sodium-phosphate cotransporter protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperphosphataemia